333 related articles for article (PubMed ID: 25268716)
1. Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin.
Spreckelmeyer S; Orvig C; Casini A
Molecules; 2014 Sep; 19(10):15584-610. PubMed ID: 25268716
[TBL] [Abstract][Full Text] [Related]
2. RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.
Jain SS; Anderson CM; DiRienzo F; Taylor IR; Jain K; Guha S; Hoque N
Chem Commun (Camb); 2013 Jun; 49(44):5031-3. PubMed ID: 23615723
[TBL] [Abstract][Full Text] [Related]
3. A novel screening method for transition metal-based anticancer compounds using zebrafish embryo-larval assay and inductively coupled plasma-mass spectrometry analysis.
Karas BF; Côrte-Real L; Doherty CL; Valente A; Cooper KR; Buckley BT
J Appl Toxicol; 2019 Aug; 39(8):1173-1180. PubMed ID: 30963621
[TBL] [Abstract][Full Text] [Related]
4. Next-generation anticancer metallodrugs.
Komeda S; Casini A
Curr Top Med Chem; 2012; 12(3):219-35. PubMed ID: 22236158
[TBL] [Abstract][Full Text] [Related]
5. Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation.
Holtkamp HU; Movassaghi S; Morrow SJ; Kubanik M; Hartinger CG
Metallomics; 2018 Mar; 10(3):455-462. PubMed ID: 29484339
[TBL] [Abstract][Full Text] [Related]
6. Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.
Leon IE; Cadavid-Vargas JF; Di Virgilio AL; Etcheverry SB
Curr Med Chem; 2017; 24(2):112-148. PubMed ID: 27554807
[TBL] [Abstract][Full Text] [Related]
7. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies.
Adhikari S; Nath P; Das A; Datta A; Baildya N; Duttaroy AK; Pathak S
Biomed Pharmacother; 2024 Feb; 171():116211. PubMed ID: 38290253
[TBL] [Abstract][Full Text] [Related]
8. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
9. Medicinal Chemistry of Gold Anticancer Metallodrugs.
Casini A; Sun RW; Ott I
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394026
[TBL] [Abstract][Full Text] [Related]
10. On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent.
Spreckelmeyer S; Estrada-Ortiz N; Prins GGH; van der Zee M; Gammelgaard B; Stürup S; de Graaf IAM; Groothuis GMM; Casini A
Metallomics; 2017 Dec; 9(12):1786-1795. PubMed ID: 29104982
[TBL] [Abstract][Full Text] [Related]
11. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
12. Protein-metallodrugs interactions: Effects on the overall protein structure and characterization of Au, Ru and Pt binding sites.
Loreto D; Ferraro G; Merlino A
Int J Biol Macromol; 2020 Nov; 163():970-976. PubMed ID: 32653380
[TBL] [Abstract][Full Text] [Related]
13. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
14. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
15. Recent insights on the medicinal chemistry of metal-based compounds: hints for the successful drug design.
Hernandes MZ; de S Pontes FJ; Coelho LC; Moreira DR; Pereira VR; Leite AC
Curr Med Chem; 2010; 17(31):3739-50. PubMed ID: 20846108
[TBL] [Abstract][Full Text] [Related]
16. Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs.
Ringhieri P; Morelli G; Accardo A
Crit Rev Ther Drug Carrier Syst; 2017; 34(2):149-183. PubMed ID: 28605318
[TBL] [Abstract][Full Text] [Related]
17. Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics.
Hartinger CG; Phillips AD; Nazarov AA
Curr Top Med Chem; 2011; 11(21):2688-702. PubMed ID: 22039871
[TBL] [Abstract][Full Text] [Related]
18. Half-Sandwich Ru(
Lenis-Rojas OA; Robalo MP; Tomaz AI; Fernandes AR; Roma-Rodrigues C; Teixeira RG; Marques F; Folgueira M; Yáñez J; Gonzalez AA; Salamini-Montemurri M; Pech-Puch D; Vázquez-García D; Torres ML; Fernández A; Fernández JJ
Inorg Chem; 2021 Mar; 60(5):2914-2930. PubMed ID: 33570919
[TBL] [Abstract][Full Text] [Related]
19. Relevance of Copper and Organic Cation Transporters in the Activity and Transport Mechanisms of an Anticancer Cyclometallated Gold(III) Compound in Comparison to Cisplatin.
Spreckelmeyer S; van der Zee M; Bertrand B; Bodio E; Stürup S; Casini A
Front Chem; 2018; 6():377. PubMed ID: 30234099
[TBL] [Abstract][Full Text] [Related]
20. Noble metal-dithiocarbamates precious allies in the fight against cancer.
Nagy EM; Ronconi L; Nardon C; Fregona D
Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
